Shots:
- Novo Nordisk has reported sub-analysis from the STEP UP trial assessing Wegovy (7.2mg, QW) vs Wegovy (2.4mg) & PBO alongside lifestyle intervention for 72wks. in >1,400 obese adults without diabetes (BMI ≥30kg/m²)
- Wegovy 7.2mg achieved 20.7% average weight loss vs 17.5% (2.4mg) & 2.4% (PBO); among early responders (≥15% loss by wk. 24), 26.9% pts achieved 27.7% weight loss vs 24.8% in 20.9% pts on 2.4mg, while non-early responders achieved 15.4% vs 13.2% weight loss
- Secondary analysis of 55 pts showed that 84% of weight loss with Wegovy (2.4 & 7.2mg) was driven by fat mass reduction, incl. >30% visceral fat reduction, while muscle mass declined only 10% with improved muscle health & preserved functional strength; data presented at ECO’26
Ref: Globenewswire | Image: Novo Nordisk | Press Release
Related News: Novo Nordisk Reports the P-IIIa (PIONEER TEENS) Trial on Oral Semaglutide for Paediatric Patients with Type 2 Diabetes
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
